A Quebec court has dismissed a legal challenge by a pharmaceutical company seeking to compel the provincial government to reimburse a specialized drug for a rare esophageal condition. The ruling reinforces the government’s authority to balance patient access with the financial constraints of a public health budget, even when a medication is the only one of its kind recognized by federal regulators.
The case centered on Jorveza, a sublingual tablet developed by Avir Pharma for patients suffering from eosinophilic esophagitis (EoE). While the drug is approved by Health Canada, the court found that the government’s refusal to add it to the public drug insurance plan was not “unreasonable.”
For the approximately 3,500 Quebecers living with EoE, the decision is more than a legal technicality. It’s a matter of daily physical struggle. EoE is a chronic, immune-mediated inflammatory disease where white blood cells (eosinophils) build up in the lining of the esophagus. This leads to inflammation and scarring, making the act of swallowing—a basic human necessity—extremely painful and often dangerous due to the risk of food impaction.
The Clinical Advantage of Sublingual Delivery
As a physician, I find the delivery mechanism of Jorveza particularly relevant to the pathology of EoE. Traditional oral medications require the patient to swallow a pill, which can be agonizing or impossible for someone with a severely inflamed esophagus. Jorveza is designed to dissolve under the tongue, allowing the medication to enter the system without passing through the affected area of the throat.
Despite this clinical utility, the path to public reimbursement in Quebec is rigorous. The Institut national d’excellence en santé et en services sociaux (INESSS) had previously recommended the drug, but with a critical caveat: the price had to be reduced. When negotiations between the manufacturer and the pan-Canadian Pharmaceutical Alliance (pCPA)—the body that negotiates prices for all provinces—reached an impasse, the Quebec government declined to cover the cost.
A Conflict of Resources and Rights
The legal battle became heated, with the Quebec Attorney General describing Avir Pharma’s lawsuit as akin to holding a “gun to the temple” of the health minister to force a listing on the public registry. Avir Pharma countered by arguing that they specialize in “niche” treatments for vulnerable populations often ignored by larger pharmaceutical giants, noting that their price of $3,500 per patient annually is consistent with European markets.
Judge Mark Phillips ultimately sided with the state. In his ruling, he noted that while the public system must provide “reasonable and equitable access” to necessary medications, it must do so within the reality of “resources that are not unlimited.”
The Economic Breakdown
| Metric | Estimated Value |
|---|---|
| Annual cost per patient | $3,500 |
| Estimated 3-year cost to RAMQ | $900,000 |
| Affected Quebec population | ~3,500 people |
The Patient Toll
For patients, the legal victory for the government feels like a systemic failure. Mathias Auger, a literature student living with EoE, expressed deep disappointment following the ruling, stating, “It’s proof that the government has no intention of helping us.”
The current landscape creates a stark divide in the quality of care based on socioeconomic status. Some patients, like Auger, have access to expensive alternative treatments—such as those originally prescribed for eczema—through private family insurance. Others are forced to pay out-of-pocket for Jorveza or rely on the government-funded alternatives, which primarily consist of cortisone-based treatments. While cortisone can manage symptoms, patients often find these replacements less effective than the targeted therapy offered by Jorveza.
This disparity highlights the ongoing tension in orphan drug legislation: the gap between a drug being “approved” for safety and efficacy by federal regulators and being “accessible” via provincial funding.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider regarding treatment options for eosinophilic esophagitis.
With the court’s decision now rendered, the status quo remains: Jorveza will not be added to the public drug plan unless a new pricing agreement is reached between Avir Pharma and the pan-Canadian Pharmaceutical Alliance. Patients currently relying on private insurance or out-of-pocket payments will continue to do so until such negotiations resume.
We invite you to share your thoughts on the balance between pharmaceutical pricing and public health access in the comments below.
